Imunon (IMNN) R&D Day 2026 summary

Pipeline overview and program updates

• IMNN-001, a locally delivered IL-12 DNA plasmid therapy, is in pivotal phase III (OVATION 3) for frontline ovarian cancer after phase II results showed significant overall survival benefit over standard of care.

• The platform uses proprietary nanoparticle delivery for local administration, overcoming historic IL-12 toxicity issues and supporting a pipeline of DNA-based medicines for multiple cancers.

• Enrollment in OVATION 3 is ahead of forecast, with rapid site activation, targeting 500 patients and completion in Q1 2029.

• The platform is being explored for other cancers (gastric, pancreatic, colorectal, glioblastoma, mesothelioma) in partnership with the NCI.

Clinical trial data and development milestones

• Phase II trial showed a 14.7-month median overall survival improvement (45.1 vs. 30.4 months) and favorable safety profile, with no cytokine release syndrome or serious immune-related adverse events.

• Recurrence-free survival was more than doubled in the experimental arm (26.1 vs 11.4 months).

• MRD study shows lower minimal residual disease rates, higher ctDNA clearance, and improved progression-free survival in the experimental arm.

• Translational data confirm local IL-12 expression, immune activation, TME remodeling, and TCR clonal expansion.

• OVATION 3 is a randomized, controlled, frontline trial with OS as the primary endpoint and two planned interim analyses.

R&D strategy and innovation priorities

• Focus on frontline ovarian cancer, aiming to shift the standard of care by integrating immunotherapy with chemotherapy and overcoming historical IL-12 barriers via local delivery.

• Platform flexibility allows encoding of other immune agents and expansion into combination strategies with checkpoint inhibitors.

• Ongoing translational research includes spatial transcriptomics, single-cell RNA/TCR-seq, and biomarker-driven patient stratification.